BML Capital Management LLC Has $2.81 Million Holdings in Kezar Life Sciences, Inc. $KZR

BML Capital Management LLC boosted its holdings in Kezar Life Sciences, Inc. (NASDAQ:KZR) by 13.5% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 720,787 shares of the company’s stock after buying an additional 85,604 shares during the period. Kezar Life Sciences accounts for approximately 2.2% of BML Capital Management LLC’s holdings, making the stock its 10th biggest position. BML Capital Management LLC owned about 9.85% of Kezar Life Sciences worth $2,811,000 at the end of the most recent quarter.

Separately, Stonepine Capital Management LLC boosted its stake in shares of Kezar Life Sciences by 69.9% in the second quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock worth $778,000 after acquiring an additional 69,859 shares during the period. 67.90% of the stock is owned by institutional investors and hedge funds.

Kezar Life Sciences Trading Up 1.9%

Shares of KZR stock opened at $6.83 on Monday. The company has a current ratio of 7.07, a quick ratio of 7.06 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $50.00 million, a price-to-earnings ratio of -0.81 and a beta of 0.56. Kezar Life Sciences, Inc. has a 12-month low of $3.53 and a 12-month high of $6.84. The stock’s 50-day moving average price is $6.26 and its 200-day moving average price is $5.42.

Analysts Set New Price Targets

Several brokerages recently issued reports on KZR. Wall Street Zen raised Kezar Life Sciences to a “hold” rating in a research note on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kezar Life Sciences in a report on Monday, December 22nd. Four equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $6.00.

Kezar Life Sciences Company Profile

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company’s research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company’s lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.